GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Akums Drugs and Pharmaceuticals Ltd

Akums Drugs Board Meeting Nov 2 Scheduled for Q2/H1 FY27 Results

BOARD ◆ Monitor Closely LOW RISK
📅 Filed on BSE: 28 Oct 2026, 03:41 PM IST  ·  BSE ID: ea5b0058-18f1-4d91-b5a0-d429a27b8fb9
View Original BSE Filing (PDF)
💡
In Simple Terms
Akums Drugs will announce its financial results for the second quarter and first half of the fiscal year on November 2nd.
🤖 AI Summary
  • Board Meeting scheduled for November 2, 2026, to approve financial results.
  • Covers un-audited standalone and consolidated results for Q2 and H1 FY27.
  • Period under review is up to September 30, 2026.
  • Trading window to reopen 48 hours post-results disclosure.
🏢 How This Affects the Company
💰
Financial Impact
The board meeting will disclose the company's financial performance for the period ending September 30, 2026, impacting investor understanding of its revenue and profitability.
⚙️
Operational Impact
The announcement of financial results will conclude the closed trading window period for company insiders and employees.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required by shareholders. Investors should await the release of financial results.
👤
Who Is Affected
All shareholders and potential investors are affected as the results will provide updated financial performance data.
🔍
Management Signal
The scheduled meeting signals management's adherence to regulatory timelines for financial reporting.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Announcement of Q2 and H1 FY27 un-audited financial results.
Reopening of the trading window post-results declaration.
Company's annual report for FY27 following these quarterly results.
LOW RISK This filing is a routine procedural intimation of a board meeting schedule.
💡 Investor Takeaway
Akums Drugs will announce its un-audited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026, on November 2, 2026.
❓ Frequently Asked Questions
When will Akums Drugs announce its financial results?
Akums Drugs will announce its un-audited financial results for the quarter and half-year ended September 30, 2026, on November 2, 2026.
What period do the upcoming Akums Drugs financial results cover?
The upcoming results will cover the quarter and half-year ended September 30, 2026.
When will the trading window reopen for Akums Drugs?
The trading window for Akums Drugs will reopen 48 hours after the declaration of the un-audited financial results.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again — explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.